Guidelines of the Association of Anesthesiologists-Intensivists, the Interregional Non-Governmental Organization Alliance of Clinical Chemotherapists and Microbiologists, the Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC), and NGO Russian Sepsis Forum "Diagnostics and antimicrobial therapy of the infections caused by multiresistant microorganisms" (update 2022)

Strains of microorganisms characterized by resistance to antimicrobial drugs used in medical organizations continue to spread In most regions of the world including Russia. It is clear that it affects both the effectiveness of antimicrobial therapy and tactics and strategy of its use not only in adults patients but also in children. The pandemic of coronavirus infection, in addition, highlighted the growing problems in treatment of invasive mycoses, the dose adjustment of antibiotics during sorption and dialysis therapy methods. These circumstances made it necessary to make adjustments to Guidelines on Diagnostics and Antimicrobial Therapy of Infections Caused by Multiresistant Strains of Microorganisms, which were prepared by a group of leading Russian experts in 2020 [1]. The submitted version of the recommendations was approved on 25.03.2022 at a joint meeting of the working group with representatives of public organizations: Association of Anesthesiologists-Intensivists, the Interregional Non-Governmental Organization Alliance of Clinical Chemotherapists and Microbiologists, the Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC), and NGO Russian Sepsis Forum. These recommendations reflect an interdisciplinary consensus opinion on approaches to the diagnosis and antimicrobial therapy of infections caused by multiresistant microorganisms. They are based on data from publications obtained from randomized trials as well as based on international clinical guidelines with a high degree of evidence.
It is rational to use the Guidelines for determining the tactics of empirical and etiotropic therapy of the most severe infections.

1. Beloborodov V.B., Gusarov V.G., Dekhnich А.V., Zamyatin M.N., Zubareva N.А., Zyryanov S.K., Kamyshova D.А., Klimko N.N., Kozlov R.S., Kulabukhov V.V., Polushin Yu.S., Rudnov V.А., Sidorenko S.V., Shlyk I.V., Edelshteyn M.V., Yakovlev S.V. Diagnostics and antimicrobial therapy of the infections caused by multiresistant microorganisms. Guidelines. Messenger of Anesthesiology and Resuscitation, 2020, vol. 17, no. 1, pp. 52-83. (In Russ.) doi: 10.21292/2078-5658-2020-17-1-52-83.

2. Gusarov V.G., Lashenkova N.N., Petrova N.V. et al. Empirical antimicrobial treatment protocols as a tool to improve the quality of emergency medical care for patients with infection in a multidisciplinary surgical in-patient unit. Meditsinsky Alfavit, 2016, vol. 33, no. 4, Neotlozhnaya Meditsina, pp. 28-24. (In Russ.)

3. Diagnostika i lechenoye mikozov v otdeleniyakh reanimatsii i intensivenoy terapii. Rossiyskiye rekomendatsii. [Diagnostics and treatment of fungal infection in critical care departments. Russian national guidelines]. N.N. Klimko, eds., 2nd ed., suppl. and amend., Moscow, Farmtek Publ., 2015, 96 p.

4. Karpov O.E., Gusarov V.G., Zamyatin M.N., Orlova O.А., Petrova L.V., Kamyshova D.А., Dementienko M.V., Gaboyan Ya.S., Pivkina А.I., Gritsenko E.А. Management of antimicrobial resistance in a hospital: current state and future prospects. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya, 2020, vol. 22, no. 4, pp. 277-286. (In Russ.) doi: 10.36488/cmac.2020.4.277-286.

5. Najgovzina N.V., Popova А.Yu., Biryukova E.E. et al. Optimization of activities aimed to control and prevent infections associated with medical care provision in the Russian Federation. ORGZDRAV, Novosti, Mneniya, Obuchenie, Vestnik VShOUZ, 2018, no. 1 (11), pp. 17–26. https://epidemiology-journal.ru/ru/archive/article/36040.

6. Opredeleniye chuvstvitelnosti k antimikrobnym preparatam. Klinicheskiye rekomendatsii. [Drug susceptibility testing. Guidelines]. Webpage of Chief Specialist of the Ministry of Health of Russia on Clinical Microbiology and Antimicrobial Resistance. https://www.antibiotic.ru/files/321/clrec-dsma2021.pdf.

7. Plan meropriyatiy na 2019-2024 gody po realizatsii Strategii preduprezhdeniya rasprostraneniya antimikrobnoy rezistentnosti v Rossiyskoy Federatsii na period do 2030 goda. [Action plan for 2019-2024 on the implementation of Strategy on Antimicrobial Resistance Prevention in the Russian Federation till 2030]. Approved by Edict no. 604-p by the RF Government as of March 30, 2019. https://www.garant.ru/products/ipo/prime/doc/71677266/

8. Popov D.А. Comparative characteristics of modern methods for carbapenemase products. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya, 2019, vol. 21, no. 2, pp. 125-133. (In Russ.)

9. Prakticheskoye rukovodstvo po monitoringu antibiotikorezistentnosti s ispolzovaniyem platformy AMRcloud. [A practical guide to monitoring antibiotic resistance using the AMRcloud platform]. https://monitoring.amrcloud.net/docs.

10. Programma SKАT (Strategiya Kontrolya Аntimikrobnoy Terapii) pri okazanii statsionarnoy meditsinskoy pomoschi: Rossiyskie klinicheskie rekomendatsii. [SATC Program (Strategy for Anrimicrobial Therapy Control) for in-patient care medical care: Russian clinical guidelines]. S.V. Yakovlev, N.I. Briko, S.V. Sidorenko et al., eds., Moscow, Izdatelstvo Pero Publ., 2018, 156 p.

11. Romanov А.V., Dekhnich А.V., Sukhorukova M.V. et al. Antibiotic resistance in nosocomial strains of Enterobacteriaceae in hospitals of Russia: results of multi-center epidemiological study of MARATHON in 2015-2016. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya, 2019, vol. 21, pp. 147-159. (In Russ.)

12. Shteynberg L.L., Upnitskiy А.А., Belousov Yu.B. Specific use of carbapenems for the treatment of nosocomial pneumonia. Lechebnoye Delo, 2014, no. 1, pp. 27–32. (In Russ.)

13. Yakovlev S.V., Suvorova M.P., Beloborodov V.B. et al. Prevalence and clinical value of nosocomial infection in the medical units of Russia: ERGINI study. Antibiotiki i Khimioterapiya, 2016, vol. 61, pp. 5-6. (In Russ.)

14. Aaftab G.P., Patil A.B., Medegar S. Multivariate analysis of risk factors for ESBL and AmpC producing Escherichia coli and Klebsiella pneumoniae at a Tertiary Care Hospital in Karnataka: A case control study. Indian Journal of Microbiology Research, 2018, vol. 5, no. 1, pp. 1–6. doi:10.18231/2394-5478.2018.0001.

15. Aloush V., Navon-Venezia, S., Seigman-Igra Y. et al. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrobial Agents and Chemotherapy, 2006, vol. 50, no. 1, pp. 43-48. doi:10.1128/AAC.50.1.43-48.2006.

16. Ashley C., Dunleavy A. The renal drug handbook: the ultimate prescribing guide for renal practitioners. 5th edition. CRC Press Taylor & Francis Group, 2019 Paperback: 1108 pp. ISBN-10: 9781138624511.

17. Bassetti M., Righi E. New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections. Current Opinion in Critical Care, 2015, vol. 21, no. 5, pp. 402–411. doi: 10.1097/MCC.0000000000000235.

18. Bassetti M., Righi E., Carnelutti A. Bloodstream infections in the intensive care unit. Virulence, 2016, vol. 7, no. 3, pp. 267–279. doi: 10.1080/21505594.2015.1134072.

19. Bush K., Jacoby G.A., Medeiros A.A. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrobial Agents and Chemotherapy, 1995, vol. 39, no. 6, pp. 1211–1233. doi: 10.1128/AAC.39.6.1211.

20. Callejo-Torre F., Bouza J.M.E., Astigarraga P.O. et al. Risk factors for methicillin-resistant Staphylococcus aureus colonisation or infection in intensive care units and their reliability for predicting MRSA on ICU admission. Europe, 2016, vol. 5, pp. 1-9. PMID: 27668900.

21. Cao B., Wang H., Sun H., et al. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. Journal of Hospital Infection, 2004, vol. 57, no. 2, pp. 112–118. doi:10.1016/j.jhin.2004.03.021.

22. Cornely O., Alastruey-Izquierdo A., Arenz D. et al. Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis., 2019, vol. 12, pp. e405–e421 doi: 10.1016/S1473-3099(19)30312-3.

23. De Pascale G., Montini L., Pennisi M.A. et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Critical Care, 2014, vol. 18, no. 3, R90. doi:10.1186/cc13858.

24. Dellit T.H. Owens R.C., McGowan J.E. et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clinical Infection Diseases, 2007, vol. 44, no. 2, pp. 159–177. doi: 10.1086/510393.

25. Doumith M., Ellington M.J., Livermore D.M. et al. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. Journal of Antimicrobial Chemotherapy, 2009, vol. 63, no. 4, pp. 659-667. doi: 10.1093/jac/dkp029.

26. Doyle D., Peirano G., Lascols C. et al. Laboratory detection of Enterobacteriaceae that produce carbapenemases. Journal of Clinical Microbiology, 2012, vol. 50, no. 12, pp. 3877–3880. doi: 10.1128/JCM.02117-12.

27. Duin D., Arias C. A., Komarow L., Chen L. et al. Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. Lancet Infectious Disease

28. European Centres for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2011. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2011.

29. Evans L., Rhodes A., Alhazzani W. et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2021. Intensive Care Med., 2021, vol. 47, no. 11, pp. 1181–1247. doi.org/10.1007/s00134-021-06506-y.

30. Falcone M., Russo A., Venditti M. et al. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clinical Infection Diseases, 2013, vol. 57, no. 11, pp. 1568–1576. doi:10.1093/cid/cit582.

31. Gazin M., Lammens, C., Goossens, H. et al. Evaluation of GeneOhm VanR and Xpert vanA/vanB molecular assays for the rapid detection of vancomycin-resistant enterococci. European Journal of Clinical Microbiology & Infectious Diseases, 2012, vol. 31, no. 3, pp. 273–276. doi: 10.1007/s10096-011-1306-y.

32. Ghibu L., Miftode E., Teodor A., et al. Risk factors for Pseudomonas aeruginosa infections, resistant to carbapenem. Revista Medico-Chirurgicala a Societatii de Medici si Naturalisti Din Lasi, 2010, vol. 114, no. 4, pp. 1012-1016. PMID: 21500452.

33. Giske C.G., Gezelius L., Samuelsen O. et al. A sensitive and specific phenotypic assay for detection of metallo‐β‐lactamases and KPC in Klebsiella pneumoniae with the use of meropenem disks supplemented with aminophenylboronic acid, dipicolinic acid and cloxacillin. Clinical Microbiology and Infection, 2011, vol. 17, no. 4, pp. 552–556. doi: 10.1111/j.1469-0691.2010.03294.x.

34. Gniadkowski M. Evolution of extended‐spectrum β‐lactamases by mutation. Clinical Microbiology and Infection, 2008, vol. 14, pp. 11-32. doi.org/10.1111/j.1469-0691.2007.01854.x.

35. Gomez F., Veita J., Laudanski K. Antibiotics and ECMO in the Adult Population - Persistent Challenges and Practical Guides. Antibiotics, 2022, no. 11, 338. https://doi.org/10.3390/antibiotics11030338.

36. Goyal D., Dean N., Neill S., et al. Risk Factors for community-acquired extended-spectrum beta-lactamase-producing enterobacteriaceae infections – a retrospective study of symptomatic urinary tract infections. Open Forum Infectious Diseases, US, Oxford University Press, 2019. vol. 6, no. 2. doi.org/10.1093/ofid/ofy357.

37. Grabein B., Graninger W., Baño J. et al. Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature. Clinical Microbiology and Infection, 2017, vol. 23, no. 6, pp. 363-372. doi: 10.1016/j.cmi.2016.12.005.

38. Greissl C., Saleh A., Hamprecht A. Rapid detection of OXA-48-like, KPC, NDM, and VIM carbapenemases in Enterobacterales by a new multiplex immunochromatographic test. European Journal of Clinical Microbiology & Infectious Diseases, 2019, vol. 38, no. 2, pp. 331-335. doi: 10.1007/s10096-018-3432-2.

39. Hahn J., Choi J.H., Chang M.J. Pharmacokinetic changes of antibiotic, antiviral, antituberculosis and antifungal agents during extracorporeal membrane oxygenation in critically ill adult patients. J. Clin. Pharm. Ther., 2017, no. 42, pp. 661–671. https://doi.org/10.1111/jcpt.12636.

40. Haley C.C., Mittal D., LaViolette A., et al. Methicillin-resistant Staphylococcus aureus infection or colonization present at hospital admission: multivariable risk factor screening to increase efficiency of surveillance culturing. Journal of Clinical Microbiology, 2007, vol. 45, no. 9, pp. 3031-3038. doi: 10.1128/JCM.00315-07.

41. Hovan M.R., Narayanan N., Cedarbaum V., Bhowmick T., Kirn T.J. Comparing Mortality in Patients with Carbapenemase-Producing Carbapenem Resistant Enterobacterales and non-Carbapenemase-Producing Carbapenem Resistant Enterobacterales Bacteremia. Diagnostic Microbiology and Infectious Disease, 2021, pp. 115505. doi: 10.1016/j.diagmicrobio.2021.115505.

42. Kao K.C., Chen C.B., Hu H.C. et al. Risk factors of methicillin-resistant Staphylococcus aureus infection and correlation with nasal colonization based on molecular genotyping in medical intensive care units: a prospective observational study. Medicine, 2015, vol. 94, no. 28, pp. e1100. doi: 10.1097/MD.0000000000001100.

43. Merchant S., Proudfoot E.M., Quadri H.N. et al. Risk factors for Pseudomonas aeruginosa infections in Asia-Pacific and consequences of inappropriate initial antimicrobial therapy: A systematic literature review and meta-analysis. Journal of Global Antimicrobial Resistance, 2018, vol. 14, pp. 33-44. doi: 10.1016/j.jgar.2018.02.005.

44. Nicolas-Chanoine M.H., Vigan M., Laouenan C., et al. Risk factors for carbapenem-resistant Enterobacteriaceae infections: a French case-control-control study. European Journal of Clinical Microbiology & Infectious Diseases, 2019, vol. 38, no. 2, pp. 383-393. doi: 10.1007/s10096-018-3438-9.

45. Ohmagari N., Hanna H., Graviss L. et al. Risk factors for infections with multidrug‐resistant Pseudomonas aeruginosa in patients with cancer. Cancer, 2005, vol. 104, no. 1, pp. 205–212. doi: 10.1002/cncr.21115.

46. Pappas P.G., Kauffman C.A., Andes D.R. et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clinical Infection Diseases, 2016, vol. 62, pp. e1–е50. doi: 10.1093/cid/civ933.

47. Paul M., Carrara E., Retamar P., et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clinical Microbiology and Infection, https://doi.org/10.1016/j.cmi.2021.11.025.

48. Platteel T.N., Stuart J.C., Voets G.M. et al. Evaluation of a commercial microarray as a confirmation test for the presence of extended‐spectrum β‐lactamases in isolates from the routine clinical setting. Clinical Microbiology and Infection, 2011, vol. 17, no. 9, pp. 1435–1438. doi: 10.1111/j.1469-0691.2011.03567.x.

49. Predic M., Delano J.P., Tremblay E. et al. Risk factors for carbapenem-resistant Enterobacteriaceae infection. American Journal of Infection Control, 2017, vol. 45, no. 6, pp. S14. doi: doi.org/10.1016/j.ajic.2017.04.271.

50. Queenan A.M., Bush K. Carbapenemases: the versatile β-lactam.

51. Red Book. 29 Edition; American Academy of Pediatrics. 2012, 1058 pp. ISBN-10: 158110703X.

52. Rybak M.J., Pharm D., Le J., et al. Therapeutic monitoring of Vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. American Journal of Health-System Pharmacy, 2020, vol. 77, is. 11, pp. 835-864. https://doi.org/10.1093/ajhp/zxaa036.

53. Sfeir M.M., Hayden J.A., Fauntleroy K.A. et al. EDTA-Modified Carbapenem Inactivation Method: a Phenotypic Method for Detecting Metallo-β- Lactamase-Producing Enterobacteriaceae. Journal of Clinical Microbiology, 2019, vol. 57, no. 5. doi:10.1128/JCM.01757-18.

54. Søraas A., Sundsfjord A., Sandven I., et al. Risk factors for community-acquired urinary tract infections caused by ESBL-producing Enterobacteriaceae-a case-control study in a low prevalence country. PloS one, 2013, vol. 8, no. 7, pp. e69581. doi:10.1371/journal.pone.0069581.

55. Taccone F.S., Laterre P.F., Spapen H. et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Critical Care, 2010, vol. 14, no. 2, pp. R53. doi.org/10.1093/cid/ciq146.

56. The Sanford Guide to Antimicrobial Therapy 2014. 44 Edition. 243 pp. ISBN-10: 1930808801.

57. Tuon F.F., Kruger M., Terreri M. et al. Klebsiella ESBL bacteremia-mortality and risk factors. Brazilian Journal of Infectious Diseases, 2011, vol. 15, no. 6, pp. 594–598. doi: 10.1590/s1413-86702011000600016.

58. Udy A.A., Baptista J.P., Lim N.L., et al. Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations. Critical Care Medicine, 2014, vol. 42, no. 3, pp. 520-527. doi: 10.1097/CCM.0000000000000029.

59. Ullmann A.J., Aguado J.M., Arikan-Akdagli S. et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin. Microbiol. Infect., 2018, vol. 24, suppl. 1, pp. e1-e38. doi: 10.1016/j.cmi.2018.01.002.

60. Vading M., Samuelsen Ø., Haldorsen B. et al. Comparison of disk diffusion, Etest and VITEK2 for detection of carbapenemase producing Klebsiella pneumoniae with the EUCAST and CLSI breakpoint systems. Clinical Microbiology and Infection, 2011, vol. 17, no. 5, pp. 668–674. doi: 10.1111/j.1469-0691.2010.03299.x.

61. Van der Zwaluw K., de Haan A., Pluister G.N., et al. The carbapenem inactivation method (CIM), a simple and low-cost alternative for the Carba NP test to assess phenotypic carbapenemase activity in gram-negative rods. PloS one, 2015, vol. 10, no. 3, pp. e0123690. doi: 10.1371/journal.pone.0123690.

62. Van Dijk K., Voets G.M., Scharringa J. et al. A disc diffusion assay for detection of class A, B and OXA-48 carbapenemases in Enterobacteriaceae using phenyl boronic acid, dipicolinic acid and temocillin. Clinical Microbiology and Infection, 2014, vol. 20, no. 4, pp. 345-349. https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(14)60285-8/pdf.

63. Wener K.M., Schechner V., Gold H.S. et al. Treatment with fluoroquinolones or with β-lactam-β-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-β-lactamase-producing Klebsiella species in hospitalized patients. Antimicrobial Agents and Chemotherapy, 2010, vol. 54, no. 5. doi:10.1128/AAC.01131-09.

64. WHO: Antimicrobial resistance: global report on surveillance, 2014. https://apps.who.int/iris/handle/10665/112642.

65. Willemsen I., Overdevest I., al Naiemi N. et al. New diagnostic microarray (Check-KPC ESBL) for detection and identification of extended-spectrum beta-lactamases in highly resistant Enterobacteriaceae. Journal of Clinical Microbiology, 2011, vol. 49, no. 8, pp. 2985–2987. doi: 10.1128/JCM.02087-10.

66. Yu Z., Pang X., Wu X., et al. Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: A meta-analysis. PloS one, 2018, vol. 13, no. 7, pp. e0201667. doi: 10.1371/journal.pone.0201667.

67. Zaha D.C., Kiss R., Hegedűs C. et al. Recent advances in investigation, prevention, and management of healthcare-associated infections (hais): resistant multidrug strain colonization and its risk factors in an Intensive Care Unit of a University Hospital. BioMed Research International, 2019. doi: 10.1155/2019/2510875.

68. Zamyatin M., Gusarov V., Petrova N. et al. Results of antimicrobial stewardship programme implementation in multidisciplinary hospital. ICU Management & Practice, 2018, vol. 18, no. 2, pp. 125–127. https://healthmanagement.org/c/icu/issuearticle/results-of-antimicrobial-stewardship-programme-implementation-in-multidisciplinary-hospitai.